Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$85.7K Sell
1,272
-73
-5% -$4.86K 0.02% 236
2026
Q1
$84.5K Buy
1,345
+4
+0.3% +$279 0.02% 214
2025
Q4
$89K Hold
1,341
0.03% 190
2025
Q3
$90.2K Sell
1,341
-424
-24% -$33.6K 0.03% 194
2025
Q2
$154K Buy
1,765
+644
+57% +$50.5K 0.05% 143
2025
Q1
$76.6K Hold
1,121
0.03% 194
2024
Q4
$87.2K Sell
1,121
-600
-35% -$44.4K 0.03% 181
2024
Q3
$115K Buy
1,721
+73
+4% +$6K 0.05% 151
2024
Q2
$187K Hold
1,648
0.09% 112
2024
Q1
$229K Hold
1,648
0.13% 112
2023
Q4
$205K Buy
+1,648
New +$168K 0.13% 108

Other funds holding DXCM

Tidemark's DXCM Position: Q2 2026 in Review

Tidemark reduced its DexCom (DXCM) stake by 5.4% in Q2 2026, selling an estimated $4.86K and leaving 1,272 shares worth $85.7K. The position accounts for 0.02% of the portfolio, ranked #236.

Tidemark first reported a position in DXCM in Q4 2023 and has held it in 11 quarters since. The position peaked at $229K in Q1 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Tidemark held 1,272 shares of DexCom worth $85.7K as of Q2 2026.
  • Tidemark sold 73 DexCom shares in Q2 2026, an estimated $4.86K.
  • DexCom made up 0.02% of Tidemark's portfolio in Q2 2026, its #236 holding.
  • Tidemark first reported a position in DexCom in Q4 2023 and has held it in 11 quarters since.
  • Tidemark's DexCom position peaked at $229K in Q1 2024.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.